carthera.eu

Webbplats analys carthera.eu

Home - Carthera

 Genereras på April 09 2026 01:59 AM

Gammal statistik? UPDATERA !

Ställningen är 61/100

SEO Innehåll

Titel

Home - Carthera

Längd : 15

Perfekt, din titel innehåller mellan 10 och 70 tecken.

Beskrivning

Revolutionizing severe brain disease treatments

Längd : 47

Idealisk, din metabeskrivning bör innehålla mellan 70 och 160 tecken (mellanslag räknas som tecken). Använd denna gratis verktyg för att räkna ut textlängden.

Nyckelord

Mycket dåligt. Vi har inte lyckats hitta några meta-taggar på din sida. Använd denna meta-tag generator, gratis för att skapa nyckelord.

Og Meta Egenskaper

Bra, din sida drar nytta utav Og.

Egendom Innehåll
locale en_US
locale:alternate fr_FR
type website
title Home - Carthera
description Revolutionizing severe brain disease treatments
url https://carthera.eu/
site_name Carthera

Rubriker

H1 H2 H3 H4 H5 H6
1 5 73 0 0 0
  • [H1] GLIOBLASTOMA and CNS DISEASES Revolutionizingbrain treatments
  • [H2] CARTHERA In a few figures
  • [H2] NO BRAIN DISEASE beyond reach
  • [H2] CLINICAL NEED AND SOLUTION Overcoming the BBB
  • [H2] Our latest news
  • [H2] AGENDA Our events
  • [H3] Our team
  • [H3] Indications
  • [H3] Strategy
  • [H3] Our ambition
  • [H3] Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel
  • [H3] Repeated blood−brain barrier opening using low-intensity pulsed ultrasound mitigates amyloid pathology
  • [H3] Carthera receives EMA expert panel endorsement for Orphan Medical Device status of SonoCloud® system
  • [H3] Carthera reaches recruitment milestone in SONOBIRD pivotal trial for recurrent glioblastoma
  • [H3] Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening
  • [H3] Effects of blood-brain barrier opening using ultrasound on tauopathies: A systematic review
  • [H3] Using ultrasound technology to open the blood brain barrier
  • [H3] Endothelial response to blood-brain barrier disruption in the human brain
  • [H3] Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound- mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas
  • [H3] Effect of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an ALS mouse model
  • [H3] Carthera receives positive opinion from French High Authority for Health on Innovation Funding scheme to treat patients with recurrent glioblastoma
  • [H3] Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas
  • [H3] Carthera receives Orphan Drug Designation (ODD) from US and EU authorities for carboplatin in malignant glioma
  • [H3] Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma
  • [H3] Carthera partners with Agenus and Northwestern University for phase 2a trial combining SonoCloud-9® with checkpoint inhibitors to treat glioblastoma
  • [H3] Positive results from phase I/II clinical trial of SonoCloud-9® in treatment of glioblastoma published in Nature Communications
  • [H3] Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial
  • [H3] Carthera enrolls first patient in pivotal trial of SonoCloud-9® device for treatment of recurrent glioblastoma
  • [H3] Series B round reaches €42M
  • [H3] Carthera signs strategic collaboration with Accord Healthcare
  • [H3] Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase I clinical trial
  • [H3] Evaluating drug delivery enhancement following ultrasound treatment
  • [H3] Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas
  • [H3] Carthera appoints Dr. Oern Stuge as chairman of board of directors
  • [H3] Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials
  • [H3] Low-Intensity Pulsed Ultrasound-Mediated Blood-Brain Barrier Opening Increases Anti-Programmed Death-Ligand 1 Delivery and Efficacy in Gl261 Mouse Model
  • [H3] Carthera closes €37.5M Series B funding round
  • [H3] Promising results from SonoCloud-9 clinical trial in combination with nab-paclitaxel have been published in Lancet Oncology
  • [H3] Carthera announces positive outcome of End-of-Phase 2 meeting with FDA for SonoCloud-9 system for treatment of recurrent glioblastoma
  • [H3] Carthera receives FDA Breakthrough Device Designation for SonoCloud-9 system
  • [H3] Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease
  • [H3] Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
  • [H3] SonoCloud® technology enhances the efficacy of immunotherapies for the treatment of brain tumor.
  • [H3] Launch of a new phase I/IIclinical trial in collaboration with Northwestern University in Chicago
  • [H3] Carthera receive €2M grant and €10.5M equity from the European Innovation Council
  • [H3] First patient enrolled in new clinical trial for SonoCloud technology in melanoma
  • [H3] Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors
  • [H3] Blood–brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors
  • [H3] Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations
  • [H3] Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives
  • [H3] Study of the means to characterize the opening of the blood-brain barrier induced by an implantable ultrasound device
  • [H3] Strategic collaboration with US-based company Lantheus
  • [H3] Latest data from the SonoCloud-9 clinical study presented at SNO on November 20-24, 2019
  • [H3] Collaboration with KIYATEC in effort to bring personalized medicine to patients stricken by brain cancer
  • [H3] FDA approval to launch a Phase 1/2a trial in glioblastoma
  • [H3] Pascal Girin, new chairman of the Board of Directors
  • [H3] Temporary blood–brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma
  • [H3] Publishing of complete results of Phase I/IIa clinical trial using the SonoCloud-1 ultrasound implant
  • [H3] Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma
  • [H3] Blood-brain barrier disruption in humans using an implantable ultrasound device: quantification with MR images and correlation with local acoustic pressure
  • [H3] ANSM approval to launch a phase I-II clinical trial for the SonoCloud-9 device
  • [H3] Closing of a €9M ($10.3M) Series B funding round
  • [H3] Potentialisation des chimiothérapies dans le traitement du glioblastome : étude des transporteurs ABC et ouverture de la barrière hémato-encéphalique par ultrasons
  • [H3] Capacitive Micro-machined Ultrasound Transducers for Interstitial High Intensity Ultrasound Therapies
  • [H3] Blood-brain barrier, cytotoxic chemotherapies and glioblastoma
  • [H3] Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate mod
  • [H3] Clinical trial of blood-brain barrier disruptionby pulsed ultrasound
  • [H3] Enhanced brain distribution ofcarboplatin ina primate model afterblood–brain barrier disruption using an implantable ultrasound device
  • [H3] Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits
  • [H3] A multi-element interstitial ultrasound applicator for the thermaltherapy of brain tumors
  • [H3] Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits
  • [H3] 30th Annual Meeting of SNO, Society for Neuro-Oncology
  • [H3] 20th Annual Meeting of EANO, European Association of Neuro-Oncology
  • [H3] Congress of Neurological Surgeons (CNS)
  • [H3] Annual Congress of EANS, European Association of Neurosurgical societies
  • [H3] 24th Annual International Symposium on Therapeutic Ultrasound (ISTU)
  • [H3] Annual meeting of ANOCEF, Association des Neuro-oncologues d'Expression Française
  • [H3] Brain Tumor Biotech Day
  • [H3] NMN symposium, Nuclear medecine and Neuro-Oncology

Bilder

Vi hittade 102 bilder på denna webbsida.

71 alt attribut är tomma eller saknas. Lägg till alternativ text så att sökmotorer enklare kan förstå innehållet i dina bilder.

Text/HTML Ratio

Ratio : 31%

Idealisk! Den här sidans text till HTML-kod förhållande är mellan 25 och 70 procent.

Flash

Perfekt, inga Flash-innehåll har upptäckts på denna sida.

Iframe

Synd, du har Iframes på webbsidorna vilket innebär att innehållet i en Iframe inte kan indexeras.

URL Rewrite

Bra. Dina adressfält ser bra ut!

Understreck i URLen

Perfekt! Inga understreck upptäcktes i din webbadress.

In-page länkar

Vi hittade totalt 10 länkar inklusive 0 länk(ar) till filer

Anchor Typ Juice
About Us Interna Passing Juice
Our Solutions Interna Passing Juice
Research & Development Interna Passing Juice
Our News Interna Passing Juice
Legal Mentions & Disclaimer Interna Passing Juice
Privacy Policy Interna Passing Juice
U.S. Expanded Access Policy Interna Passing Juice
Sitemap Interna Passing Juice
Contact (EN) Interna Passing Juice
Kookline Externa Passing Juice

SEO Nyckelord

Nyckelord Moln

carthera barrier request brain ultrasound read publication scientific more glioblastoma

Nyckelord Konsistens

Nyckelord Innehåll Titel Nyckelord Beskrivning Rubriker
publication 69
scientific 34
carthera 32
request 32
brain 32

Användbarhet

Url

Domän : carthera.eu

Längd : 11

Favikon

Bra, din webbplats har en favicon.

Utskriftbart

Vi kunde inte hitta CSS för utskrifter.

Språk

Bra. Ditt angivna språk är en.

Dublin Core

Denna sida drar inte nytta utav Dublin Core.

Dokument

Doctype

HTML 5

Encoding

Perfekt. Din deklarerade teckenuppsättning är UTF-8.

W3C Validity

Errors : 0

Varningar : 0

E-post Sekretess

Varning! Minst en e-postadress har påträffats i klartext. Använd gratis antispam skydd för att dölja e-post från spammare.

Föråldrad HTML

Bra! Vi har inte hittat några föråldrad HTML taggar i din HTML.

Hastighets Tips

Utmärkt, din webbplats använder inga nästlade tabeller.
Synd, din webbplats använder sig utav inline stilar.
Bra, din webbplats har få CSS-filer.
Perfekt, din webbplats har få Javascript filer
Perfekt, din webbplats utnyttjar gzip.

Mobil

Mobiloptimering

Apple Ikon
Meta Viewport Tagg
Flash innehåll

Optimering

XML Sitemap

Bra, din webbplats har en XML sitemap.

https://carthera.eu/sitemap_index.xml

Robots.txt

https://carthera.eu/robots.txt

Bra, din webbplats har en robots.txt fil.

Analytics

Saknas

Vi hittade inte någon analysverktyg på din webbplats.

Webbanalys program kan mäta besökare på din webbplats. Du bör ha minst ett analysverktyg installerat, men det kan också vara en bra ide att installera två för att dubbelkolla uppgifterna.

PageSpeed Insights

Enhet
Kategorier

Free SEO Testing Tool

Free SEO Testing Tool är en fri SEO verktyg som hjälper dig att analysera din webbplats